Abionyx News and Activities
Presence
Abionyx is a biotechnology firm that focuses on the discovery and development of novel therapies to treat complex diseases, with a particular specialization in lipid metabolism. The firm's primary target customers include healthcare providers and patients affected by these conditions.
- Bio-active lipids
- Therapeutic proteins
- Genetic therapies
Employees: 20
Abionyx is one of the...
Abionyx is a company listed under the stock ticker ABNX (FR).
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Abionyx
- Cyrille Tupin, Chief Executive Officer and Director
- Karen Noel, Director
- Emmanuel Huynh, Chairman of the Board
Create your alert
to follow the executive moves at Abionyx.
Biotechnology
Abionyx has 2,340 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).
Popular M&A news in Biotechnology
- Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
- Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
- The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).
Popular contacts in Biotechnology
News
Press releases by Abionyx
- CERENIS - THERAPEUTICS - Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH
- CERENIS - THERAPEUTICS - Publication of 2016 Registration Document
- CERENIS - THERAPEUTICS - Cash position and update on clinical developments for Q1 2017
Social media about Abionyx
- Abionyx on Wikipedia, Google News & Yahoo Finance
- Abionyx on LinkedIn, Twitter & YouTube
